Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study - Overman, MJ; McDermott, R; Leach, JL (Lancet Oncol, 2017)
et al.